Lenalidomide and Blinatumomab for the Treatment of Relapsed Non-Hodgkin Lymphoma

Summary

This phase I trial studies the side effects and best dose of lenalidomide and blinatumomab when given together in treating patients with non-Hodgkin lymphoma that has returned after a period of improvement (relapsed). Biological therapies, such as lenalidomide, use substances made from living organisms that may stimulate or suppress the immune system in different ways and stop cancer cells from growing. Blinatumomab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread.

Timeline

Start

2016-11-15

Primary completion

2025-11-24

Completion

2025-11-24

Drugs

Indications